On Wednesday, TRACON Pharmaceuticals (NASDAQ: TCON) will report its last quarter's earnings. Here is Benzinga's take on the company's release.
Earnings and Revenue
Sell-side analysts are expecting TRACON Pharmaceuticals's loss per share to be near 46 cents on sales of $1 million.
In the same quarter last year, TRACON Pharmaceuticals reported a loss per share of 45 cents per shar. If the company were to report inline earnings when it publishes results Wednesday, earnings would be up 2.22 percent.
The company's reported EPS has stacked up against analyst estimates in the past like this:
|Quarter||Q3 2017||Q2 2017||Q1 2017||Q4 2016|
Over the last 52-week period, shares are down 44.23 percent. Given that these returns are generally negative, long-term shareholders won't be happy going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.
Over the past 90 days, analysts' have generally adjusted their estimates lower for EPS and revenues. Analysts generally rate TRACON Pharmaceuticals stock as Buy. The strength of this rating has maintained conviction over the past three months.
TRACON Pharmaceuticals' Q4 is scheduled to hold a conference call at 4:30 p.m. ET and it can be accessed here.
See more from Benzinga
- Portola Pharmaceuticals Q4 Earnings Preview
- Mylan Q4 Earnings Preview
- La Quinta Holdings Q4 Earnings Preview
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.